close

Clinical Trials

Date: 2017-12-21

Type of information: Completion of the trial

phase:

Announcement:

Company: Sanifit (Spain - Switzerland)

Product: SNF472 - hexasodium phytate

Action mechanism:

  • SNF472 (hexasodium phytate) selectively blocks the pathological cardiovascular calcification progression. The FDA and the EMA have granted SNF472 orphan drug designation for the treatment of calciphylaxis. Preclinical models have already demonstrated that SNF472 reduces the progression of calcium deposition in blood vessels and cardiac tissue.

Disease: calciphylaxis

Therapeutic area: Rare diseases - Cardiovascular diseases

Country: UK, USA

Trial details:

Latest news:

  • • On December 21, 2017, Sanifit announced that the last patient's last visit occurred in the Phase II study of SNF472, its lead candidate for the treatment of calciphylaxis (calcific uraemic arteriolopathy, CUA) . The trial was done in collaboration with internationally recognised calciphylaxis experts in the US, Spain, Germany and the UK. Sanifit expect to present and publish the data from the trial on healing of skin ulcers in early 2018.
  • In addition to the calciphylaxis program, SNF472 is being developed for the reduction in progression of cardiovascular calcification in dialysis patients. A Phase IIb trial is currently underway for this separate indication.
   

Is general: Yes